Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

levonorgestrol, with estradiol 156
luteinizing hormone (LH) 64–5
magnesium, diet supplements 145
magnetic resonance spectroscopy (MRS) 102–3, 102, 105–6
management of PMS 149–59
measures of impairment 35
menstrual cycle 63–81, 66
endometrial changes 66–7
ovarian and pituitary hormones 65, 66
ovarian steroidogenesis 63–5
phases 65
pubertal onset 63
milk, dietary 153
model of PMS/PMDD 171–7
monamine oxidase A (MAOA), and serotonin 162, 163, 165
mood symptoms 86–8, 117–20, 162, 172–3
affective adaptation, actions of ovarian steroids 86–8
and GABA system 71–2
5-hydroxyindole acetic acid (5-HIAA) 72
negative mood, action of ovarian steroids 117–20
progesterone-induced 117–18, 162, 172–3
Moos MDQ scale 28
neurocircuitry
neuroimaging 87, 99–102
targeting by ovarian steroids 173
neuroimaging 99–102
fMRI 100–1, 101, 175
and GABA 99–107
modulation of neurocircuitry by ovarian steroids 175
MRS 102–3, 102, 105–6
neurocircuitry 87
PET 99, 101–2, 102,174
SPECT 101, 102
neuroregulation
affective adaptation 86–8
by ovarian steroids 86–8
neurotransmitter physiology 69–81, 161–7
endogenous opioid peptides 75–7
GABA system 69–72, 75
serotonin system 72–5, 162–6
nomenclature of PMS 55
obsessive–compulsive disorder 51
Oenothera biennis (evening primrose) 144
oophorectomy 126–7, 156–7, 172
opioid peptides, endogenous 75–7
affective symptoms 76
oral contraceptives 109–11
clinical trials 44, 110–11
combined (COCP) 121, 153–4
osteoporosis 126–7
ovarian cycle suppression 121–9, 172
COCP 121
danazol 112, 124
and estradiol 172–3
estradiol patches and implants 122–4
GnRH agonists 113, 155–6, 172
GnRH analogues 124, 125
hysterectomy and salpingo–oophorectomy 126–7,
156–7, 172
progesterone and progestogens 125–6
ovarian steroids
actions 85–6
affective adaptation and PMS 86–8
negative mood 117–20
neuromodulatory effects 86–8
steroid receptor function 177
steroidogenesis 63–5, 83–97
2-cell-2-gonadotropin hypothesis 64
fluctuations in menstrual cycle 65–6
synthetic pathways 84
ovariectomy 126–7, 156–7, 172
ovary, fetal 63
panic disorder 51–2
paroxetine, clinical trials 43
pathophysiology of PMS 83–107, 171–7
neuroimaging and GABA 99–107
ovarian steroids 83–97, 117–20
somatic symptoms 22, 24–5, 75, 161–6
pituitary hormones 65, 66
PMS/PMDD, definitions 49–50
positron emission tomography (PET) scan 99, 101–2,
102, 174
pregnanolone
and GABAA receptor 70, 176, 118
properties 162
structure and synthesis 71
Premenstrual Symptoms Screening Tool 29–31, 33
prevalence studies 37–9
non-US countries 39
with retrospective criteria 39
with/without prospective confirmation 37–9
progesterone 117–20, 125–6
as hormone therapy 112, 156
metabolites
GABAA receptor 70, 117
mediation of behavioral effects of ovarian
steroids 162, 176
symptom-provoking action 71, 117–18, 162, 176
synthesis 71, 162
see also allopregnanolone; pregnanolone
and ovarian suppression 172–3
progesterone receptor antagonist RU-486 172
progesterone replacement
historical aspects 3–6
‘luteal phase abnormality’ 88, 125
no deficiency exists 125, 172
progesterone-induced mood symptoms 117–18, 162, 172–3
progestogens, intolerance 123–4
psychiatric illness, comorbidity of PMS 49–54
psychopharmacology 154–5
psychotropic therapies 131–9
pubertal onset 63
quality of life (QoL)
disability adjusted life years (DALYs), epidemiology
of PMS 11
INDEX 183